Evaluation of results observed in a prospective study on the long term follow-up of 100 patients with neurocysticercosis (NC) is reported. Praziquantel (PZQ) was administered to the patients at their admission to the study. Follow-up time was over two years in 63 patients (maximum 118 months). Clinical conditions, TC findings and CSF changes were taken into account for the evaluation. Patients were evaluated periodically during the follow-up. Sactisfatory results predominate (72.5%). Sactisfatory results maintain a close relationship with clinical forms of the disease: good results predominate among those patients with clinical manifestations of NC which are not marked by intracranial hypertension of progressive character. Results of this long term follow-up evaluation favour the administration of PZQ to patients with NC.